2616704-22-2
Chemical Structure
CL2A
- CAS No.: 2616704-22-2
- Formula:C50H79N9O16
- Molecular Weight:1062.21
IUPAC Name: (S)-N-((1-(38-amino-34-((4-(hydroxymethyl)phenyl)carbamoyl)-28,32-dioxo-3,6,9,12,15,18,21,24,30-nonaoxa-27,33-diazaoctatriacontyl)-1H-1,2,3-triazol-4-yl)methyl)-4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexane-1-carboxamide
InChIKey: CJDCJOXHKQMGGB-DBSIFAAZSA-N
SMILES: O=C(NC1=CC=C(CO)C=C1)[C@H](CCCCN)NC(COCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCN2N=NC(CNC(C3CCC(CN4C(C=CC4=O)=O)CC3)=O)=C2)=O)=O
Biological Activity: CL2A is a claevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. Labetuzumab govitecan used this linker[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CL2A | CL2A is a claevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. Labetuzumab govitecan used this linker. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
